MARKET

VOR

VOR

Vor Biopharma Inc.
NASDAQ
13.16
+1.09
+9.03%
After Hours: 13.13 -0.03 -0.26% 19:49 02/06 EST
OPEN
12.31
PREV CLOSE
12.07
HIGH
13.80
LOW
12.25
VOLUME
1.05M
TURNOVER
--
52 WEEK HIGH
65.80
52 WEEK LOW
2.622
MARKET CAP
546.40M
P/E (TTM)
-0.0340
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at VOR last week (0126-0130)?
Weekly Report · 5d ago
Wall Street Analysts Are Bullish on Top Healthcare Picks
TipRanks · 01/30 11:30
Vor Bio files to sell 13.88M shares of common stock for holders
TipRanks · 01/29 21:21
Vor Biopharma Files Prospectus For Offering 13.876M Common Shares
Benzinga · 01/29 21:20
VOR BIOPHARMA INC - PROSPECTUS FOR RESALE OF 13.9 MLN SHARES OF COMMON STOCK BY THE SELLING STOCKHOLDERS - SEC FILING
Reuters · 01/29 21:16
Weekly Report: what happened at VOR last week (0119-0123)?
Weekly Report · 01/26 09:08
Weekly Report: what happened at VOR last week (0112-0116)?
Weekly Report · 01/19 09:09
Vor Biopharma Unveils Telitacicept Data Targeting B Cell-Driven Autoimmune Diseases
Reuters · 01/15 20:06
More
About VOR
Vor Biopharma Inc. is a clinical-stage biotechnology company transforming the treatment of autoimmune diseases. The Company is focused on rapidly advancing telitacicept, a dual-target fusion protein, through Phase III clinical development and commercialization to address serious autoantibody-driven conditions worldwide. Telitacicept is an investigational recombinant fusion protein designed to treat autoimmune diseases by selectively inhibiting BLyS (BAFF) and APRIL - two cytokines essential to B cell and plasma cell survival. This dual-target mechanism reduces autoreactive B cells and autoantibody production, key drivers of autoimmune pathology. Telitacicept is approved in China for systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and generalized myasthenia gravis (gMG). A global Phase III clinical trial in gMG is underway across the United States, Europe, and South America to support potential approval in the United States and Europe.

Webull offers Vor Biopharma Inc stock information, including NASDAQ: VOR real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, VOR stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading VOR stock methods without spending real money on the virtual paper trading platform.